<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689376</url>
  </required_header>
  <id_info>
    <org_study_id>16040</org_study_id>
    <nct_id>NCT01689376</nct_id>
  </id_info>
  <brief_title>Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)</brief_title>
  <official_title>Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this Managed Access Program is to provide regorafenib to patients diagnosed&#xD;
      with metastatic and / or unresectable GIST who have progressed after standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This &quot;Managed Access Program&quot; covers the different types of programs in the participating&#xD;
      countries (including compassionate use program, named patient program, cohorts e.g. ATU in&#xD;
      France, etc).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib (BAY73-4506)</intervention_name>
    <description>160 mg BAY73-4506, 3 weeks on drug, 1 week off drug</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed consent (IC) and data protection clarification obtained before any&#xD;
             specific treatment related procedures. Patients or their legal representative must be&#xD;
             able to understand and willing to sign a written IC.&#xD;
&#xD;
          -  Male or female patients &gt;= 18 years of age&#xD;
&#xD;
          -  Patients with histologically confirmed metastatic and / or unresectable GIST&#xD;
&#xD;
          -  At least imatinib and sunitinib as prior treatment regimens with progression on or&#xD;
             intolerance to imatinib and sunitinib&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of =&lt; 1&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             before entering the program until at least 8 weeks after the last regorafenib&#xD;
             administration in the program. The treating physician or a designated associate is&#xD;
             requested to advise the patient on how to achieve adequate birth control. Adequate&#xD;
             contraception is defined in this program as any medically recommend method (or&#xD;
             combination of methods) as per standard of care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with regorafenib&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to starting regorafenib&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             pregnancy test performed a maximum of 7 days before start of treatment, and a negative&#xD;
             result must be documented before start of regorafenib.&#xD;
&#xD;
          -  Congestive heart failure New York Heart Association (NYHA) class 2&#xD;
&#xD;
          -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3&#xD;
             months)&#xD;
&#xD;
          -  Myocardial infarction less than 6 months before start of regorafenib&#xD;
&#xD;
          -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are&#xD;
             permitted)&#xD;
&#xD;
          -  Uncontrolled hypertension. (Systolic blood pressure &gt; 140 mmHg or diastolic pressure &gt;&#xD;
             90 mmHg despite optimal medical management)&#xD;
&#xD;
          -  Pleural effusion or ascites that causes respiratory compromise (National Cancer&#xD;
             Institute's common terminology criteria for adverse events [NCI-CTCAE] v.4.0 Grade &gt;=&#xD;
             2 dyspnea)&#xD;
&#xD;
          -  Ongoing infection NCI-CTCAE v.4.0 Grade &gt; 2&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with&#xD;
             antiviral therapy&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Patients with evidence or history of any bleeding diathesis, irrespective of severity&#xD;
&#xD;
          -  Any hemorrhage or bleeding event NCI-CTCAE v. 4.0 Grade &gt;= 3 within 4 weeks prior to&#xD;
             the start of regorafenib&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Renal failure requiring hemo- or peritoneal dialysis&#xD;
&#xD;
          -  Dehydration NCI-CTCAE v.4.0 Grade &gt;= 1&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the program&#xD;
&#xD;
          -  Known hypersensitivity to regorafenib, the drug class, or excipients in the&#xD;
             formulation&#xD;
&#xD;
          -  Any illness or medical conditions that are unstable or could jeopardize the safety of&#xD;
             the patient and his / her compliance in the program&#xD;
&#xD;
          -  Interstitial lung disease with ongoing signs and symptoms&#xD;
&#xD;
          -  Persistent proteinuria of NCI-CTCAE v.4.0 Grade 3 (&gt; 3.5 g/24 hours)&#xD;
&#xD;
          -  Patients unable to swallow oral medications&#xD;
&#xD;
          -  Any malabsorption condition&#xD;
&#xD;
          -  Unresolved toxicity higher than NCI-CTCAE v.4.0 Grade 1 (excluding alopecia, anaemia,&#xD;
             and hypothyroidism) attributed to any prior therapy / procedure&#xD;
&#xD;
          -  Concomitant participation or participation within the last 30 days in a clinical trial&#xD;
&#xD;
          -  Non-permissible concomitant medications and procedures (systemic anti-cancer therapy&#xD;
             including cytotoxic therapy, signal transduction inhibitors, immunotherapy and&#xD;
             hormonal therapy or any experimental therapies; Tyrosine Kinase Inhibitors (TKIs);&#xD;
             bone marrow transplant or stem cell rescue; use of biologic response modifiers, such&#xD;
             as granulocyte colony stimulating factor (G CSF), within 3 weeks prior to entering the&#xD;
             program; St John's Wort; grapefruit and grapefruit juice; all traditional medicines&#xD;
             with an anti-cancer indication)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

